Cancer Currencies: Making and Marketing Resources in a First-in-Human Drug Trial in Denmark
Research output: Chapter in Book/Report/Conference proceeding › Book chapter › Research › peer-review
Standard
Cancer Currencies : Making and Marketing Resources in a First-in-Human Drug Trial in Denmark. / Hillersdal, Line; Svendsen, Mette Nordahl.
Precision Oncology and Cancer Biomarkers. 1. ed. Cham : Springer, 2022. p. 45-60 (Human Perspectives in Health Sciences and Technology, Vol. 5).Research output: Chapter in Book/Report/Conference proceeding › Book chapter › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - CHAP
T1 - Cancer Currencies
T2 - Making and Marketing Resources in a First-in-Human Drug Trial in Denmark
AU - Hillersdal, Line
AU - Svendsen, Mette Nordahl
PY - 2022
Y1 - 2022
N2 - Welfare state service delivery is increasingly driven by public-private collaborations and strategies aimed at turning the provision of core welfare services into a profitable business at an international scale. Particularly within cancer treatment development, the cost of medical research is increasing, and many policymakers see partnerships between private and public partners as mandatory to sustain public welfare services. But how do welfare state practices and values intersect with commercial interests as cancer research becomes increasingly entangled with big pharma interests? We explore this question by investigating the collaboration between a public hospital in Denmark and a multi-national pharmaceutical company and the practical work involved in setting up and running early cancer drug trials for personalised medicine. Based on ethnographic research we analyse how competition, investment and exchange practices shape how welfare resources for personalised medicine are defined, produced, and offered. We argue that qualities facilitated by the welfare state – i.e., fast-tracking trial procedures, high-quality data and high compliance of research subjects – become currencies transactable on the global market for drug development.
AB - Welfare state service delivery is increasingly driven by public-private collaborations and strategies aimed at turning the provision of core welfare services into a profitable business at an international scale. Particularly within cancer treatment development, the cost of medical research is increasing, and many policymakers see partnerships between private and public partners as mandatory to sustain public welfare services. But how do welfare state practices and values intersect with commercial interests as cancer research becomes increasingly entangled with big pharma interests? We explore this question by investigating the collaboration between a public hospital in Denmark and a multi-national pharmaceutical company and the practical work involved in setting up and running early cancer drug trials for personalised medicine. Based on ethnographic research we analyse how competition, investment and exchange practices shape how welfare resources for personalised medicine are defined, produced, and offered. We argue that qualities facilitated by the welfare state – i.e., fast-tracking trial procedures, high-quality data and high compliance of research subjects – become currencies transactable on the global market for drug development.
U2 - 10.1007/978-3-030-92612-0_4
DO - 10.1007/978-3-030-92612-0_4
M3 - Book chapter
SN - 9783030926113
T3 - Human Perspectives in Health Sciences and Technology
SP - 45
EP - 60
BT - Precision Oncology and Cancer Biomarkers
PB - Springer
CY - Cham
ER -
ID: 336366055